Vanguard Global Advisers
CTSO icon

Vanguard Global Advisers’s Cytosorbents Corp CTSO Stock Holding History

Vanguard Global Advisers’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.19K Hold
13,865
– – ﹤0.01% 3548
2026
Q1 		$7.85K Buy
+13,865
New +$9.46K ﹤0.01% 3505

Other funds holding CTSO

AC
Avenir Corporation Alexandria, Virginia $821M AUM 4.23% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
SC
Skylands Capital Milwaukee, Wisconsin $814M AUM 32.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Global Advisers's CTSO Position: Q2 2026 in Review

Vanguard Global Advisers held its Cytosorbents Corp (CTSO) position steady in Q2 2026 at 13,865 shares worth $5.19K. The position accounts for ﹤0.01% of the portfolio, ranked #3548.

Vanguard Global Advisers first reported a position in CTSO in Q1 2026 and has held it in 2 quarters since. The position peaked at $7.85K in Q1 2026. 50 funds tracked by Wall St. Rank hold CTSO as of Q2 2026.

  • Vanguard Global Advisers held 13,865 shares of Cytosorbents Corp worth $5.19K as of Q2 2026.
  • Vanguard Global Advisers left its Cytosorbents Corp share count unchanged in Q2 2026.
  • Cytosorbents Corp made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3548 holding.
  • Vanguard Global Advisers first reported a position in Cytosorbents Corp in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Cytosorbents Corp position peaked at $7.85K in Q1 2026.
  • 50 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.